^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ETS inhibitor

    Related drugs:
    5d
    A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma (clinicaltrials.gov)
    P2, N=15, Completed, Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting --> Completed | N=30 --> 15
    Trial completion • Enrollment change
    |
    ONCT-216
    1m
    ETS1 potentiates pancreatic Pyroptosis in mice with acute pancreatitis by regulating the NKIRAS1/NF-κB Axis. (PubMed, Int Immunopharmacol)
    This study reveals that ETS1 transcriptionally suppresses NKIRAS1, activating NF-κB signaling and promoting pyroptosis and pancreatic injury in AP. Targeting ETS1 may represent a promising therapeutic strategy.
    Preclinical • Journal
    |
    ETS1 (ETS Proto-Oncogene 1)
    |
    ONCT-216 • Bay11-7082
    2ms
    A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma (clinicaltrials.gov)
    P2, N=30, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    ONCT-216
    over1year
    Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma. (PubMed, J Clin Oncol)
    TK216 administered as 14-day continuous infusion with or without vincristine was well tolerated and showed limited activity at the RP2D in R/R ES.
    P1/2 data • Journal
    |
    FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
    |
    vincristine • ONCT-216
    almost2years
    A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma (clinicaltrials.gov)
    P2, N=30, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ONCT-216
    over2years
    The Small-Molecule E26-Transformation-Specific Inhibitor TK216 Attenuates the Oncogenic Properties of Pediatric Leukemia. (PubMed, Genes (Basel))
    Priming the leukemic cells with 5-Azacitidine enhanced the cytotoxic effects of TK216 on pediatric leukemia cells...Consistent with this, TK216 also potentiated the cytotoxic effects of Bcl-2 inhibition in venetoclax-resistant cells. The sustained survival benefit provided to leukemic cells in the presence of bone-marrow-derived conditioned media is also found to be modulated by TK216. Taken together, our data indicates that TK216 could be a promising targeted therapeutic agent for the treatment of acute myeloid and B-lymphoid leukemia.
    Journal
    |
    MCL1 (Myeloid cell leukemia 1)
    |
    Venclexta (venetoclax) • azacitidine • ONCT-216
    over3years
    ETS-Transcription Factor inhibitors are effective in TERT promoter mutated meningioma cells in vitro (EANO 2022)
    Conclusion : In summary, our results indicate that ETS transcription factor inhibition by TK216 exerts antitumour activity in our TERT promoter mutant meningioma cell model. Additionally, the sensitivity against TK216 is superior to YK-4-279 and therefore TK216 may represent a promising new therapeutic option for patients with aggressive, TERT promoter mutated meningioma.
    Preclinical • PARP Biomarker
    |
    PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ANXA5 (Annexin A5)
    |
    TP53 mutation • TERT mutation • TERT promoter mutation • PARP1 expression
    |
    Oncomine™ Comprehensive Assay v3M
    |
    ONCT-216
    over3years
    TK216 targets microtubules in Ewing sarcoma cells. (PubMed, Cell Chem Biol)
    Using reconstituted microtubule (MT) polymerization in vitro and cell-based chemical probe competition assays, we demonstrate that TK216 acts as an MT destabilizing agent. This work defines the mechanism of cytotoxicity of TK216, explains the synergy observed with vincristine, and calls for a reexamination of ongoing clinical trials with TK216.
    Journal
    |
    EWSR1 (EWS RNA Binding Protein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
    |
    EWSR1-FLI1 fusion
    |
    vincristine • ONCT-216
    almost4years
    TK216-01: TK216 in Patients With Relapsed or Refractory Ewing Sarcoma (clinicaltrials.gov)
    P1/2, N=85, Terminated, Oncternal Therapeutics, Inc | N=45 --> 85 | Trial completion date: Mar 2024 --> Jun 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2023 --> May 2022
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    EWSR1 (EWS RNA Binding Protein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
    |
    ONCT-216
    almost4years
    TK216-01: TK216 in Patients With Relapsed or Refractory Ewing Sarcoma (clinicaltrials.gov)
    P1/2, N=45, Active, not recruiting, Oncternal Therapeutics, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EWSR1 (EWS RNA Binding Protein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
    |
    ONCT-216